Document:

Execution Copy: August 1, 2013

 

 

 

 

ANDA SECURITY AGREEMENT

 

THIS ABBREVIATED NEW DRUG APPLICATION
SECURITY AGREEMENT (the “Agreement”), dated as of August 1, 2013, between Elite Laboratories, Inc.,
a Delaware corporation (“Elite”) and its parent, Elite Pharmaceuticals, Inc., a Nevada corporation (collectively,
“Debtors”), and Mikah Pharma LLC, a limited liability company organized under the laws of the State of
Delaware ("Secured Party");

 

WHEREAS, Debtors and Secured Party
are parties to that certain Secured Convertible Note Due 2016 of even date herewith (herein, as at any time amended, extended,
restated, renewed or modified, the "Note"); and

 

WHEREAS, it is a condition to the
willingness of Secured Party to enter into the Asset Purchase Agreement by and between Secured Party and Elite of even date (the
“Purchase Agreement”), to sell the Purchased Assets (as defined in the Purchase Agreement) to Elite and
to accept the Note as consideration under the Purchase Agreement for the Purchased Assets that Debtors enter into this ADNA Security
Agreement and grant to Secured Party the security interest provided for herein; and

 

WHEREAS, in order to induce Secured
Party to accept the Note and the debt evidenced thereby as consideration for the Purchased Assets under the Purchase Agreement,
Debtors have agreed to grant to Secured Party a security interest in and to and mortgage on the Abbreviated New Drug Applications
included in the Purchased Assets (collectively, the "ANDAs"). This Agreement is being executed contemporaneous
with the Purchase Agreement and the Note under which Secured Party is granted a lien on and security interest in and to, the ANDAs,
whereby Secured Party shall have the right to foreclose on the ANDAs in the event Secured Party alleges the occurrence of an Event
of Default under the Note. Terms not defined herein shall have the meaning set forth in the Note and terms not defined herein or
in the Note shall have the meaning set forth in the Purchase Agreement.

 

NOW, THEREFORE, in consideration
of the premises, and other good and valuable consideration the sufficiency of which is hereby acknowledged, Debtors hereby agree
with Secured Party as follows:

 

1. To secure any and all obligations of
Debtors to Secured Party under the Note and Transaction Documents, including but not limited to, repayment of the obligations of
Debtors under the Note, Debtors hereby convey, grant, assign, pledge, transfer, mortgage, and create in favor of Secured Party
a security interest in and to and mortgage on all of Debtors’ right, title and interest in and to the Purchased Assets (as
that term is defined in the Purchase Agreement), including without limitation any and all rights under any notices or agreements
related thereto (collectively, the “Collateral”).

 

    	 

    	 

    

 

2. Debtors represent, covenant and warrant
that:

 

(a) the ANDAs are subsisting;

 

(b) Elite is the sole and exclusive owner
of the entire and unencumbered right, title and interest in and to the Collateral, free and clear of any liens, charges and encumbrances,
including without limitation pledges, assignments, registered user agreements and covenants by Debtors not to sue third persons;

 

(c) Debtors have the unqualified right
to enter into this Agreement and perform its terms; and

 

(d) All ANDAs on file with the Food and
Drug Administration (the "FDA") were prepared in accordance with applicable law.

 

3. Debtors agree that, until all of the
obligations under the Note shall have been satisfied in full, Debtors will not, without Secured Party's prior written consent,
which consent will not be unreasonably withheld, enter into any agreement to transfer or sell any of the Collateral.

 

3A. Perfection of Secured Party’s
Interests.

 

(a) Debtors agree to cooperate and join,
at their expense, with Secured Party in taking such steps as are reasonably necessary, in Secured Party’s judgment, to perfect
or continue the perfected status of the security interests granted hereunder, including, without limitation, the execution and
delivery of any financing statements, amendments thereto and continuation statements, the delivery of chattel paper, documents
or instruments to the Secured Party, the obtaining of landlords’ and mortgagees’ waivers required by Secured Party,
the notation of encumbrances in favor of Secured Party on certificates of title, and the execution and filing of any collateral
assignments and any other instruments reasonably requested by Secured Party to perfect its security interest in any and all of
the Collateral.

 

(b) Secured Party may at any time and from
time to time, file financing statements, continuation statements, filings with the FDA or other federal agencies, and amendments
thereto, that describe the Collateral and which contain any other information required by the Uniform Commercial Code or federal
law for the sufficiency or filing office acceptance of any financing statement, continuation statement, other filing, or amendment,
including whether a Debtor is an organization, the type of organization and any organization identification number issued to the
Debtor. Debtors agree to furnish any such information to the Secured Party promptly upon request. Any such financing statements,
continuation statements, other filing or amendments may be signed by Secured Party on behalf of Debtors, and may be filed at any
time in any jurisdiction, whether or not Revised Article 9 of the Uniform Commercial Code is then in effect in that jurisdiction.
The foregoing grant of authority to sign and file such documents on behalf of Debtors is a power of attorney coupled with an interest
and shall be irrevocable for the life of this Agreement. Secured Party, or its designee, as attorney-in-fact, will not be liable
for any acts or omissions, or for any error of judgment or mistake of fact or law, except for gross negligence, or willful misconduct.
This power, being coupled with an interest, is irrevocable until all obligations of Debtors to Secured Party under the Note and
Transaction Documents have been indefeasibly paid in full and performed and satisfied.

 

    	2

    	 

    

 

 

(c) Debtors shall, at any time and from
time to time, take such steps as Secured Party may reasonably require for Secured Party, (i) to obtain an acknowledgment, in form
and substance satisfactory to the Secured Party, of any third party having possession of any of the Collateral that the third party
holds such Collateral for the benefit of the Secured Party, and (ii) otherwise to insure the continued perfection and priority
of Secured Party’s security interest in any of the Collateral and of the preservation of its rights therein.

 

4. If any Event of Default under the Note
or this Agreement shall have occurred, Secured Party shall have, in addition to all other rights and remedies given it by this
Agreement, those allowed by law and the rights and remedies of a Secured Party under the Uniform Commercial Code as enacted in
any jurisdiction in which the ANDAs may be deemed located and, without limiting the generality of the foregoing, Secured Party
may immediately, without demand of performance and without notice or demand whatsoever to Debtor, all of which are hereby expressly
waived, and without advertisement, sell at public or private sale or otherwise realize upon, assign, transfer, license or otherwise
dispose of, including but not limited to, transferring the ANDAs in New Jersey or elsewhere, all or from time to time any of the
ANDAs, or any interest which Debtors may have therein, and after deducting from the proceeds of sale or other disposition of any
and all of the ANDAs all expenses (including all expenses for broker's fees and legal services), apply the residue of such proceeds
to Debtors’ obligations to Secured Party under the Note. Any remainder of the proceeds after payment in full of Debtors’
obligations owing to Secured Party under the Note and Transaction Documents including but not limited to the repayment in full
of Debtors’ obligations to Secured Party under the Note shall be paid over to Debtor. Notice of any sale or other disposition
of the ANDAs shall be given to Debtors at least five (5) days before the time of any intended public or private sale or other disposition
of the ANDAs is to be made, which Debtors hereby agree shall be reasonable notice of such sale or other disposition. At any such
sale or other disposition, Secured Party or any holder of the Note may, to the extent permissible under applicable law, purchase
the whole or any part of the ANDAs free from any right of redemption on the part of Debtors, which right is hereby waived and released.
Debtors waive the benefit of any marshalling doctrine with respect to Secured Party’s exercise of its rights hereunder. Debtors
grant a royalty-free license to Secured Party for all patents, service marks, trademarks, trade names, copyrights, computer programs
and other intellectual property and proprietary rights sufficient to permit Secured Party to exercise all rights granted to Secured
Party under this Agreement.

 

5. At such time as Debtors shall completely
satisfy all of Debtors’ obligations to Secured Party under the Note and Transaction Documents including but not limited to
repayment of the obligations of Debtors under the Note, this Agreement and the Note shall terminate and Secured Party shall execute
and deliver to Debtors all documents and other instruments as may be necessary or proper to terminate this Agreement and re-vest
in Elite the ANDAs, subject to any disposition thereof which may have been made by Secured Party pursuant hereto.

 

    	3

    	 

    

 

6. Any and all fees, costs and expenses,
of whatever kind or nature, including reasonable attorney's fees and legal expenses incurred by Secured Party in connection with
the consummation of this transaction, the filing or recording of any documents (including all taxes in connection therewith) in
public offices, the payment or discharge of any taxes, counsel fees, maintenance fees, encumbrances or otherwise protecting, maintaining
or preserving the ANDAs, or in defending or prosecuting any actions or proceedings arising out of or related to the ANDAs, shall
be borne and paid by Debtors on demand by Secured Party and until so paid shall become part of Debtors’ obligations under
the Note. Debtors hereby agree to execute and deliver to Secured Party any and all additional documents requested by Secured Party
regarding the ANDAs at any time and from time to time in its discretion to carry out and enforce the terms and conditions of this
Agreement.

 

7. Debtors shall have the duty, through
counsel acceptable to Secured Party, to complete the approval process of the ANDAs, pending as of the date of this Agreement or
thereafter until all of Debtors’ obligations under the Note shall have been paid in full, to file and provide further information
and documentation and to do any and all acts which are necessary or desirable to seek approval of the ANDAs and to preserve and
maintain all rights to the ANDAs. Any expenses incurred in connection with the ANDAs shall be borne by Debtors. Debtors shall not
abandon any ANDAs without the consent of Secured Party, which consent shall not be unreasonably withheld.

 

8. If Debtors breach or fail to comply
with any of the terms and conditions of this Agreement or upon the occurrence of an Event of Default under the Note or any of the
Transaction Documents, Debtors hereby authorize and empower Secured Party to make, constitute and appoint any officer or agent
of Secured Party as Secured Party may select, in its exclusive discretion, as Debtors’ true and lawful attorney-in-fact,
with the power to endorse Debtors’ name on all applications, documents, papers and instruments of every kind and nature necessary
or desirable, including without limitation, for Secured Party to approve, use, own, transfer, assign, license or dispose of the
ANDAs, or necessary or desirable for Secured Party to assign, pledge, convey or otherwise transfer title in or dispose of the ANDAs
to Secured Party or anyone else, including without limitation any and all Forms 356H, and/or such other forms as the FDA shall
require. Debtors hereby ratify all that such attorney shall lawfully do or cause to be done by virtue hereof. This power of attorney
shall be irrevocable for the life of this Agreement. Secured Party, or its designee, as attorney-in-fact, will not be liable for
any acts or omissions, or for any error of judgment or mistake of fact or law, except for gross negligence, or willful misconduct.
This power, being coupled with an interest, is irrevocable until all obligations of Debtors to Secured Party under the Note and
Transaction Documents have been indefeasibly paid in full and performed and satisfied.

 

9. If Debtors fail to comply with any of
their obligations hereunder, Secured Party may do so in Debtors’ name or in Secured Party's name, but at Debtors’ expense,
and Debtors hereby agree to reimburse Secured Party in full for all expenses, including reasonable attorney's fees, incurred by
Secured Party in approving, protecting, defending and maintaining the ANDAs.

 

10. No course of dealing between Debtors
and Secured Party, nor any failure to exercise, nor any delay in exercising, on the part of Secured Party, any right power or privilege
hereunder or under the Note shall operate as a waiver thereof; nor shall any single or partial exercise of any right, power or
privilege hereunder or thereunder preclude any other or further exercise thereof or the exercise of any other right, power or privilege.

 

    	4

    	 

    

 

11. All of Secured Party's rights and remedies
with respect to the ANDAs, whether established hereby or by the Note or the other Transaction Documents, or by any other agreements
or by law shall be cumulative and may be exercised singularly or concurrently.

 

12. The provisions of this Agreement
are severable, and if any clause or provision shall be held invalid and unenforceable in whole or in part in any
jurisdiction, then such invalidity or unenforceability shall affect only such clause or provision, or part thereof, in such
jurisdiction, and shall not in any manner affect such clause or provision in any other jurisdiction, or any other clause or
provision of this Agreement in any jurisdiction.

 

13. This Agreement is subject to modification
only by a writing signed by the parties.

 

14. The benefits and burdens of this Agreement
shall inure to the benefit of and be binding upon the respective successors and permitted assigns of the parties.

 

15. The validity and interpretation of
this Agreement and the rights and obligations of the parties shall be governed by the laws of the State of New Jersey.

 

16. The provisions of Sections 13 and 14
the Note are hereby incorporated by reference into this Agreement. To the extent that there is a conflict between the provisions
of this Agreement and Sections 13 and 14 of the Note, the provisions of this Agreement shall govern.

 

 

[Signature Page follows]

 

    	5

    	 

    

  

Execution Copy: August 1, 2013

 

 

IN WITNESS WHEREOF, this ANDA Security Agreement
is execution hereof as of the day and year first above written.

 

 

Debtors:

 

 

	 	ELITE LABORATORIES, INC.	 	 	ELITE PHARMACEUTICALS, INC.
	 	 	 	 	 
	 	 	 	 	 
	By:	 	 	By:	 
	Name:	 	 		Name:
	Title:	 	 		Title:

 

 

 

Secured Party:

 

 

	 	MIKAH PHARMA LLC	 
	 	 	 
	 	 	 
	By:	 	 
	 	Nasrat Hakim	 
	 	Title:	 

 

 

    	6

    	 

    

   

STATE OF NEW JERSEY )

) ss.:

COUNTY OF                         )

 

 

On the____________day of August, in the year
2013, before me personally came ___________ to me known, who, being by me duly sworn, did depose and say that he resides in _________________;
that he is the _______________ of Elite Laboratories, Inc., the corporation described in and which executed the above instrument;
and that he signed his name thereto by authority of the board of directors of said corporation.

 

 

______________________

Notary Public

 

STATE OF NEW JERSEY )

) ss.:

COUNTY OF                         )

 

 

On the                                       day
of August, in the year 2013, before me personally came _________, to me known, who, being by me duly sworn, did depose and
say that he resides in ___________; that he is the  of Elite Pharmaceuticals, Inc., the corporation described in and
which executed the above instrument; and that he signed his name thereto by authority of the board of directors of said
corporation.

 

 

______________________

Notary Public

 

STATE OF NEW JERSEY )

) ss.:

COUNTY OF                        )

 

 

On the ______________day of August, in
the year 2013, before me personally came Nasrat Hakim, to me known, who, being by me duly sworn, did depose and say that he resides
in ______________; that he is the  ________________of Mikah Pharma LLC., the limited liability company described in and which executed
the above instrument; and that he signed his name thereto upon his authority as manager of said company.

 

 

__________________________

Notary Public

 

    	7

    	 

    

SPECIAL POWER OF ATTORNEY

 

STATE OF NEW JERSEY)

) ss.:

COUNTY OF  _______________)

 

 

KNOW ALL MEN BY THESE PRESENTS,
that Elite Laboratories, Inc., a Delaware corporation, having an address at 165 Ludlow Avenue, Northvale, New Jersey 07647 ("Debtor"),
pursuant and subject to the terms and conditions contained in an Abbreviated New Drug Application Security Agreement dated as of
the date hereof (as amended, modified, restated or supplemented from time to time, the "Security Agreement"),
hereby appoints and constitutes Mikah Pharma LLC with an address at 20 Kilmer Drive, Hillsborough, New Jersey, 08844 ("Secured
Party"), its true and lawful attorney, with full power of substitution, and with full power and authority to perform the
following acts on behalf of Debtor:

 

1. Assigning, selling, transferring, or
otherwise disposing of all right, title and interest of Debtor in and to all Abbreviated New Drug Applications ("ANDA")
of Debtor specified in the Security Agreement, and all registrations and recordings thereof, and all pending applications therefor,
and for the purpose of the recording, registering and filing of, or accomplishing any other formality with respect to, the foregoing,
and to execute and deliver any and all agreements, documents, instruments of assignment or other writings necessary or advisable
to effect such purpose;

 

2. To execute any and all documents, statements,
certificates or other writings necessary or advisable in order to effect the purposes described above as Secured Party may in its
sole discretion determine including without limitation any and all Forms 356H and/or such other forms as the FDA may require.

 

This power of attorney is made pursuant
to the Security Agreement, dated the date hereof, between Debtor and Secured Party and may not be revoked until the payment in
full of all Debtors’ obligations under the Security Agreement.

 

 

 

 

	 	 	 	ELITE LABORATORIES, INC.	 
	 	 	 	 	 
	ATTEST:	 	 	 	 
	 	 	 By:	 	 
	 	 		Name:	 
	 	 		Title:	 
	 	 	 	 	 
	 	 	 	 	 
	Name:	 	 	 	 
	Title	 	 	 	 

 

    	8

    	 

    

 

 

STATE
OF NEW JERSEY )

) ss.:

COUNTY OF  _______________)

 

 

On the______________ day of August, in
the year 2013, before me personally came ___________, to me known, who, being by me duly sworn, did depose and say that he resides
in______________; that he is the______________ of Elite Laboratories, Inc., the corporation described in and which executed the above instrument;
and that he signed his name thereto by authority of the board of directors of said corporation.

 

__________________________

Notary Public

 

 

    	9EXECUTION COPY; August 1, 2013

 

EMPLOYMENT AGREEMENT

 

This agreement (“Agreement”)
is made on August 1, 2013, by and between Elite Pharmaceuticals, Inc., a Nevada corporation (“Company”), and
Nasrat Hakim (“Executive”).

 

WHEREAS, Company desires
Executive to be Company President and Chief Executive Officer (“CEO”) and Executive desires to provide employment services
to Company in such a capacity and in accordance with the terms of this Agreement.

 

In consideration of
the mutual promises and considerations herein contained, the parties hereby agree as follows:

 

A G R E E M E N T:

1.Employment.

 

1.1Company hereby
employs Executive in the capacity of President & CEO reporting to the Board of Directors (the “Board”)
effective August 2, 2013.  Executive hereby accepts such employment, subject to the terms herein contained. In
such capacity Executive (a) shall perform such functions and duties as are required in the Company’s Bylaws and (b) shall
report to and receive direction from the Board (the “Duties”). Executive shall devote such time and effort to his Duties
as are reasonably necessary for him to perform such Duties in a competent and professional manner.

 

2.Compensation
and Benefits.

 

2.1.Salary.
During the Term (as defined below), Company shall pay to Executive a base salary at the annual rate of Three Hundred Fifty Thousand
Dollars ($350,000) (the “Salary”). The Salary shall be paid in shares of Company’s Common Stock (“Stock”)
pursuant to the Company’s current procedures for paying Company executives in Stock (i.e., with regards to the method of
computing the number of Shares to be issued and the timing of such issuances, provided the timing is no later than March 15th
following the end of the calendar year for which payment is being made). Notwithstanding the foregoing, the payment of such Shares
shall be made in a manner that does not violate Section 409A of the Internal Revenue Code of 1986, as amended (“Section
409A”) as discussed in Section 3.2.8 below.

 

2.2.Bonuses.

 

2.2.1Annual
Bonus. Executive shall be entitled to an annual bonus equal to 100% of Executive’s annual salary (“Annual Bonus”).
The Annual Bonus shall be paid in Stock in accordance with the same methods utilized in Section 2.1 above. The Annual Bonus shall
be paid on or before March 15th following the end of the calendar year for which payment is being made. During the Term,
the Board shall set up specific milestones to be achieved within each calendar year (“Annual Milestones”) and
the amount of the Annual Bonus shall be payable upon the achievement of such Annual Milestones.

 

2.2.2Discretionary
Bonuses. In addition to the Annual Bonus, the Board may award discretionary bonuses from time to time.

 

8K 2013 8 5 Exhibit 10 4 Hakim Employment Agreement.DOC

    	 	1	 

    	 

    

  

2.3.Executive
Benefits.

 

2.3.1.Expenses.
Company shall promptly reimburse Executive for all reasonable and documented travel, entertainment and other business expenses
actually and properly incurred by him in relation to Company’s business. No such expense reimbursement shall be allowed with
regard to such expenses that exceed $10,000 unless such expenses have been pre-approved by Company in writing. Such expense reimbursement
shall include reasonable hotel accommodations and/or housing incurred by Executive specifically related to his duties under this
Agreement against receipts or other appropriate written evidence of such expenditures as required by
the appropriate Internal Revenue Service regulations or by Company.

 

2.3.2.Company
Plans. Executive shall be entitled to participate in such employee benefit plans and programs as Company may from time
to time generally offer or provide to senior executive officers of Company, including medical and retirement plans. Nothing
in the foregoing shall limit or restrict Company’s discretion to amend, revise or terminate any benefit or plan without notice
to or consent of Executive.

 

2.3.3.Vacation.
Executive shall be entitled to four (4) weeks of paid vacation per Fiscal Year, pro rated for
periods of less than a full Fiscal Year.

 

2.3.4.Automobile
Allowance. During the Term, Company shall reimburse Executive One Thousand Five Hundred Dollars ($1,500) per month for
automobile expenses and/or car lease.

 

3.Employment
Term; Termination.

 

3.1.Employment
Term. Executive’s employment hereunder shall commence on August 1, 2013 (the “Commencement Date”).

 

3.2.Events of
Termination. Executive’s employment may be terminated as follows:

 

3.2.1Termination
for Cause. This Agreement may be terminated by Company for Cause. For purposes of this Agreement, “Cause”
justifying the termination of this Agreement by Company is defined as: (1) failure or refusal to perform the services required
hereunder; (2) a material breach by Executive of any of the terms of this Agreement; or (3) Executive’s conviction of a crime
that either results in imprisonment or involves embezzlement, dishonesty, or activities injurious to Company or its reputation.
Following termination pursuant to this subsection, Company’s only obligation to Executive shall be to pay to Executive all
accrued Annual Salary and all accrued vacation time (both payable in Stock computed in the same manner as set forth in Section
2.1) and any reasonable and necessary business expenses incurred by Executive in connection with his duties, all to the Date of
Termination and payable in a lump sum, less applicable deductions and withholdings, as soon as administratively practicable following
Executive’s termination, but in no event later than March 15th following the end of the calendar year in which
such termination occurs. Notwithstanding the foregoing, any expense reimbursement will take place no later than the time required
under Section 409A.

 

    	2

    	 

    

  

3.2.2Disability.
This Agreement may be terminated by Company upon at least thirty (30) days’ written notice if Executive is prevented by illness,
accident or other disability (mental or physical) from performing the essential functions of the position for one or more periods
cumulatively totaling three (3) months during any consecutive twelve (12) month period. In the event this Agreement is terminated
pursuant to this subsection, Company shall pay to Executive all accrued Salary, pro rata Annual Bonus, and all accrued vacation
time (all payable in Stock computed in the same manner as set forth in Section 2.1) and any reasonable and necessary business expenses
incurred by Executive in connection with his duties, all to the Date of Termination and payable in a lump sum, less applicable
deductions and withholdings. In addition, Company shall pay to Executive severance payments in an amount equal to one (1) year
of Executive’s Salary, payable in Stock computed in the same manner as set forth in Section 2.1 and payable in a lump sum,
less applicable deductions and withholdings, as soon as administratively practicable (but in no event later than 60 days) following
Executive’s termination, but in no event later than March 15th following the end of the calendar year in which
such termination occurs (“Disability Severance Payments”). Disability Severance Payments made by Company to
Executive pursuant to this Section 3.2.2 are conditioned on the Executive signing a Confidential Severance Agreement and Release.
Notwithstanding the foregoing, any expense reimbursement will take place no later than the time required under Section 409A

 

3.2.4Death.
This Agreement shall be automatically terminated in the event of Executive’s death during the Term of employment. In the
event this Agreement terminates upon Executive’s death, Company shall pay Executive’s estate or beneficiary, as applicable,
all accrued Salary, pro rated Annual Bonus and all accrued vacation time (both payable in Stock computed in the same manner as
set forth in Section 2.1) and any reasonable and necessary business expenses incurred by Executive in connection with his duties,
all to the Date of Termination and all payable in a lump sum, less applicable deductions and withholdings, as soon as administratively
practicable (but in no event later than 60 days) following Executive’s termination, but in no event later than March 15th
following the end of the calendar year in which such termination occurs.

 

3.2.5Without
Cause.  This Agreement may be terminated by Company without Cause by giving Executive notice at least thirty (30) days
prior to the effective date (“Date of Termination”); provided that Company pays Executive each
of the following:

 

(i)Company shall
pay Executive severance payments, payable in Stock computed in the same manner as set forth in Section 2.1 (the “Severance
Payments”) in an amount equal to two (2) years’ Salary at the rate in effect upon the Date of Termination,
less applicable deductions and withholdings, as soon as administratively practicable (but in no event later than 60 days)
following Executive’s termination, but in no event later than March 15th following the end of the calendar year
in which such termination occurs. In addition, Company shall pay to Executive all accrued Salary, prorated Annual Bonus and all
accrued vacation time (both payable in Stock computed in the same manner as set forth in Section 2.1) and any reasonable and necessary
business expenses incurred by Executive in connection with his duties, all to the Date of Termination and payable in a lump sum,
less applicable deductions and withholdings, as soon as administratively practicable (but in no event later than 60 days)
following Executive’s termination, but in no event later than March 15th following the end of the calendar year
in which such termination occurs.

 

    	3

    	 

    

  

(ii)If the Company
has a health insurance plan for its employees and Executive is covered under such plan, provided that Executive timely elects continuation
coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), Company shall
pay, on Executive’s behalf, the portion of premiums of Executive’s group health insurance, including coverage for Executive’s
eligible dependents, that Company paid immediately prior to Executive’s separation of employment with Company (“COBRA
Payments”) for a period of twelve (12) months following the Date of Termination (“COBRA Period”).
Company will pay such COBRA Payments for Executive’s eligible dependents only for coverage for which those dependents were
enrolled immediately prior to the date of Executive’s separation of employment. Executive will continue to be required to
pay that portion of the premium of Executive’s health coverage, including coverage for Executive’s eligible dependents,
that Executive was required to pay as an active employee immediately prior to the date of Executive’s separation of employment.
For the balance of the period that Executive is entitled to coverage under COBRA after the COBRA Period, if any, Executive shall
be entitled to maintain coverage for Executive and Executive’s eligible dependents at Executive’s sole expense.

 

(iii)The Severance
Payments and the COBRA Payments (if any) shall be paid so long as Executive is not in breach of any term of this Agreement, including,
without limitation, Sections 4, 5, 6, 7 and 8. The Severance Payments and COBRA Payments (if any) made by Company to, or on behalf
of, Executive are conditioned on the Executive signing a Severance Agreement and Release.

 

3.2.6Resignation.
This Agreement may be terminated by Executive for any reason or no reason at all by giving notice to Company of Executive’s
resignation at least sixty (60) days prior to the effective resignation date. Following termination pursuant to this subsection
3.2.6, Company’s only obligation to Executive shall be to pay to Executive all accrued Salary and all accrued vacation time
(both payable in Stock computed in the same manner as set forth in Section 2.1) and any reasonable and necessary business expenses
incurred by Executive in connection with his duties, all to the Date of Termination and payable in a lump sum, less applicable
deductions and withholdings no later than March 15th following the end of the calendar year in which such termination
occurs.

 

3.2.7. Termination
Upon Change of Control. Upon “Change of Control” as defined in section 3.3.1, Executive is entitled to a payment
in an amount equal to two (2) years Annual Salary in effect upon the Date of Termination, less applicable
deductions and withholdings, payable in Stock computed in the same manner as set forth in Section 2.1 as soon as administratively
practicable (but in no event later than 60 days) following Executive’s termination, but in no event later than March 15th
following the end of the calendar year in which such termination occurs. Executive also shall be entitled to a continuation of
his Executive benefits for a period of (2) two years from the Date of Termination. In addition, Company shall pay to Executive
all accrued Annual Salary, pro rated Annual Bonus and all accrued vacation time (both payable in Stock computed in the same manner
as set forth in Section 2.1) and any reasonable and necessary business expenses incurred by Executive in connection with his duties,
all to the Date of Termination and payable in a lump sum, less applicable deductions and withholdings,
as soon as administratively practicable (but in no event later than 60 days) following Executive’s termination, but in no
event later than March 15th following the end of the calendar year in which such termination occurs. In addition any
securities of the Company owned by Executive and subject to vesting schedules shall immediately vest.

 

    	4

    	 

    

  

3.2.8Section
409A Compliance.

 

(i)All in-kind benefits
provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive
during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable,
but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the
expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect
the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year. Such right to reimbursement
or in-kind benefits is not subject to liquidation or exchange for another benefit.

 

(ii)To the extent
that any of the payments or benefits provided for in Section 3 are deemed to constitute non-qualified deferred compensation benefits
subject to Section 409A of Code, the following interpretations apply: (A) Any termination of the Executive’s employment triggering
payment of benefits under Section 3 must constitute a “separation from service” under Section 409A(a)(2)(A)(i) of the
Code and Treas. Reg. §1.409A-1(h) before distribution of such benefits can commence. To the extent that the termination of
the Executive’s employment does not constitute a separation of service under Section 409A(a)(2)(A)(i) of the Code and Treas.
Reg. §1.409A-1(h) (as the result of further services that are reasonably anticipated to be provided by the Executive to the
Company or any of its affiliates, at the time the Executive’s employment terminates), any benefits payable under Section
3 that constitute deferred compensation under Section 409A of the Code shall be delayed until after the date of a subsequent event
constituting a separation of service under Section 409A(a)(2)(A)(i) of the Code and Treas. Reg. §1.409A-1(h). For purposes
of clarification, this Section 3.2.8(ii) shall not cause any forfeiture of benefits on the Executive’s part, but shall only
act as a delay until such time as a “separation from service” occurs. (B) If the Executive is a “specified employee”
(as that term is used in Section 409A of the Code and regulations and other guidance issued thereunder) on the date his separation
from service becomes effective, any benefits payable under Section 3 that constitute non-qualified deferred compensation under
Section 409A of the Code shall be delayed until the earlier of (1) the business day following the six-month anniversary of the
date his separation from service becomes effective, and (2) the date of the Executive’s death, but only to the extent necessary
to avoid such penalties under Section 409A of the Code. On the earlier of (3) the business day following the six-month anniversary
of the date his separation from service becomes effective, and (4) the Executive’s death, the Company shall pay the Executive
in a lump sum the aggregate value of the non-qualified deferred compensation that the Company otherwise would have paid the Executive
prior to that date under Section 5(b) of this Agreement. (C) It is intended that each installment of the payments and benefits
provided under Section 3 shall be treated as a separate “payment” for purposes of Section 409A of the Code; and neither
the Company nor the Executive shall have the right to accelerate or defer the delivery of any such payments or benefits except
to the extent specifically permitted or required by Section 409A of the Code.

 

(iii)It is the intention
of the parties that payments or benefits payable under this Agreement not be subject to the additional tax imposed pursuant to
Section 409A of the Code. To the extent such potential payments or benefits could become subject to such Section, the parties shall
cooperate to amend this Agreement with the goal of giving Executive the economic benefits described herein in a manner that does
not result in such tax being imposed.

 

    	5

    	 

    

 

3.2.9.Termination
of Employment. This Agreement shall terminate simultaneously with the termination of Executive’s employment for any reason;
provided, that the covenants set forth in Sections 3, 4, 5, 6, 7 and 8 of this Agreement shall survive the termination of
this Agreement to the extent provided in such Sections.

 

3.3.Definitions.

 

3.3.1.“Change
of Control” Defined. The term “Change of Control” shall mean (a) the acquisition of Company pursuant
to a consolidation of Company with, or merger of Company with or into, any other Person with the result of which the holders of
Company’s voting stock immediately prior to such transaction hold less than fifty (50%) percent of the combined voting power
after giving effect to such transaction; (b) the sale of all or substantially all of the assets or capital stock of Company to
any other Person; or (c) securities of Company representing greater than fifty (50%) percent of the combined voting power of Company’s
then outstanding voting securities are acquired by a Person, or group of related Persons, in a single transaction or series of
related transactions.

 

3.3.2.“Notice
of Termination” Defined. “Notice of Termination” means a written notice that indicates the specific
termination provision relied upon by Company or Executive.

 

3.3.3.“Date
of Termination” Defined. “Date of Termination” means such date as Executive’s employment expires
as written in the Notice of Termination.

 

4.Conflicts
of Interest. Company and Executive acknowledge that Executive is the owner, President and CEO of Mikah Pharma LLC (“Mikah”).
Company and Executive will sign a separate agreement concluding any potential conflict to the satisfaction of both parties and
Executive agrees to comply with such agreement.

 

5.Proprietary
Information.

 

5.1Executive represents
and warrants to Company that (i) Executive is not subject to any limitation or agreement restricting employment by Company or performance
of Executive’s Duties hereunder, and (ii) neither Executive nor any third party has any right or claim to Executive’s
work produced on behalf of Company or using the property, personnel, or facilities of Company. Executive shall not misappropriate
proprietary rights of Company or any third party.

 

    	6

    	 

    

 

5.2Executive further
agrees not to make, use, disclose to any third party, or permit to be made, used, or disclosed, any records, plans, papers, articles,
notes, memoranda, reports, lists, records, drawings, sketches, specifications, software programs, data, or other materials of any
nature relating to any matter within the scope of the business of Company or concerning any of its dealings or affairs (“Materials”),
whether or not developed, in whole or in part, by Executive and whether or not embodying Confidential Information (defined below),
otherwise than for the benefit of Company. Executive shall not, on and after the Date of Termination, use, disclose, or permit
to be used or disclosed, any such Materials, it being agreed that all such Materials shall be and remain the sole and exclusive
property of Company. Immediately upon the Date of Termination, Executive shall deliver all such Materials, and all copies thereof,
to Company, at its designated office.

 

6.Non-Competition;
Non-Solicitation; Anti-Raiding; Non-Disparagement. Without the prior written approval of the Board, Executive shall
not, directly or indirectly, during his employment and until the end of one (1) year after the Date of Termination (however such
termination occurs, including, without limitation, termination pursuant to Section 3.2):

 

6.1Solicit, offer
employment to, otherwise attempt to hire, or assist in the hiring of any employee or officer of Company or any of its Affiliates;
(ii) encourage, induce, assist or assist others in inducing any such person to terminate his or her employment with Company
or any of its Affiliates; or (iii) in any way interfere with the relationship between Company or any of its Affiliates and
their employees; or

 

6.2Make any public
statement or perform or do any other act prejudicial or injurious to the reputation or goodwill of Company or any of its Affiliates
or otherwise interfere with the business of Company or any of its Affiliates.

 

6.3Notwithstanding
anything to the Contrary in Subsection 6.1, Mikah shall have the right to continue the business previously established for the
Morphine Sulfate ODT and Trimipramine, products including manufacturing and/or sales of the product through third party contracts.

 

7.Confidentiality.

 

7.1The term “Confidential
Information” shall include, but not be limited to confidential information and the workpapers, concepts, formulas, techniques,
strategies, components, programs, reports, studies, memoranda, correspondence, materials, manuals, records, data, technology, financial
information, products, plans, research, service, design information, procedures, methods, documentation, policies, pricing, billing,
customer lists and leads, and any other technical data, information and know-how which relates to products or customers or potential
customers or suppliers or potential suppliers or are otherwise useful in the parties' businesses, and which one of the parties
considers proprietary and desires to maintain confidential. Confidential Information is entitled to protection hereunder whether
or not such information is oral or written, whether or not such information is identified as such by an appropriate stamp or marking
on each document provided or, if orally first provided, identified at that time as proprietary or confidential. In addition, Confidential
Information shall include information developed by the Executive in the performance of his Duties under this Agreement. All such
Confidential Information is extremely valuable and is intended to be kept secret to Company; is the sole and exclusive property
of Company or its Affiliates; and, is subject to the restrictive covenants set forth herein. The term Confidential Information
shall not include any information generally available to the public or publicly disclosed by Company (other than by the act or
omission of Executive), information disclosed to Executive by a third party under no duty of confidentiality to Company or its
Affiliates, information that Executive can demonstrate was in his possession prior to the date of this Agreement or Executive can
demonstrate was independently developed by him without the use or assistance of Confidential Information, or information required
by law or court order to be disclosed by Executive.

 

    	7

    	 

    

 

 

7.2Executive shall
not, without Company’s prior written approval, use, disclose, or reveal to any person or entity any of Company’s Confidential
Information, except as required in the ordinary course of performing duties hereunder. Executive shall not use or attempt to use
any Confidential Information in any manner which has the possibility of injuring or causing loss, whether directly or indirectly,
to Company or any of its Affiliates.

 

7.3In the event that
Executive’s employment with Company is terminated for any reason whatsoever, he shall return to Company, promptly upon Company’s
written request therefore, any documents, photographs, tapes, discs, memory devices, and other property containing Confidential
Information which were received by him during his employment, without retaining copies thereof.

 

8Assignment
of Intellectual Property.

 

8.1.Executive shall
promptly disclose to Company any and all Inventions (as defined below). Executive shall promptly communicate to Company all information,
details and data pertaining to any Inventions in such form as Company requests. Executive agrees that Inventions, patents and patent
applications are the property of Company, and any and all rights, titles or interests in and to Inventions, patents or patent applications
which Executive may have in any and every jurisdiction are hereby assigned in full. Whenever Executive is requested to do so by
Company, during or after the Term, Executive shall, at the Company’s sole cost and expense, promptly execute and deliver
any and all applications, assignments or other documents or instruments reasonably deemed necessary or advisable by Company to
apply for and obtain Letters Patent of the United States or any foreign country or to otherwise protect, confirm or establish Company’s
full and exclusive interests in any Inventions. The obligations set forth in this Section 8.1 shall be binding upon the successors,
assigns, executors, administrators and other legal representatives of Executive.

 

8.2Any and all Works
for Hire (as defined below) shall be considered “works made for hire” under the copyright laws of the United States
or property of Company under applicable federal, state, local and foreign trademark laws (as appropriate). Executive shall promptly
communicate to Company any and all Works for Hire, and any and all information, details and data pertaining to any Works for Hire,
in such form as Company requests. To the extent that Works for Hire fail to qualify as (A) “works made for hire” under
the copyright laws of the United States or any other jurisdiction or (B) property of Company under applicable federal, state, local
or foreign trademark laws, Executive hereby assigns each Work for Hire and all right, title and interest therein in any and every
jurisdiction to Company. Whenever Executive is requested to do so by Company, during or after the Term, Executive shall, at the
Company’s sole cost and expense, promptly execute and deliver any and all applications, assignments or other documents or
instruments reasonably deemed necessary or advisable by Company to apply for and confirm and effectuate full and exclusive ownership
of Works for Hire in Company, including, but not limited to, ownership of any moral rights under the copyright law of any nation,
or any other rights under the intellectual property laws of any nation. The obligations set forth in this Section 8.2 shall be
binding upon the successors, assigns, executors, administrators and other legal representatives of Executive.

 

    	8

    	 

    

 

8.3If a court declares
that any term or provision of this Section 8 is invalid or unenforceable, the parties to this Agreement agree that the court making
the determination of invalidity or unenforceability shall have the power to reduce the scope, duration or area of the term or provision,
to delete specific words or phrases, or to replace any invalid or unenforceable term or provision with a term or provision that
is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision,
and this Agreement shall be enforceable as so modified.

 

8.4Definitions.

 

8.4.1“Inventions”
Defined. “Inventions” means any and all inventions, discoveries, improvements, patent, copyrights and/or
other property rights, whether or not patented or patentable made, conceived, created, developed or contributed to by Executive
during the Term which are (i) directly or indirectly related to the business, operations or activities of the Company or any of
its subsidiaries or affiliates, (ii) directly or indirectly related to Executive’s employment by, or performance of other
services (including as a director, manager, officer, advisor, agent, representative, consultant or other independent contractor)
for, the Company or any of its Affiliates, or (iii) based upon Confidential Information.

 

8.4.2“Work
for Hire” Defined. “Work for Hire” means any and all sales approaches, sales material, training material,
computer software, documentation, other copyrightable works or any other intellectual property (including, but not limited to,
materials or services subject to trademark or service mark registration, but excluding Inventions) made, conceived, created, developed
or contributed to by Executive during the Term and which are (i) directly or indirectly related to the business, operations or
activities of the Company or any of its Affiliates, (ii) directly or indirectly related to Executive’s employment by, or
performance of other services (including as a director, manager, officer, advisor, agent, representative, consultant or other independent
contractor) for, the Company or any of its Affiliates, or (iii) based upon Confidential Information.

 

9.Acknowledgments;
Equitable Remedies. Executive acknowledges that the covenants contained in Sections 4, 5, 6, 7 and 8, including those related
to duration, geographic scope, and the scope of prohibited conduct, are reasonable and necessary to protect the legitimate interests
of Company. He further acknowledges that the covenants contained in Sections 4, 5, 6, 7 and 8 are designed, intended, and necessary
to protect, and are reasonably related to the protection of, Company’s proprietary information, to which he will be exposed
and with which he will be entrusted. Specifically, without limitation, Executive is entrusted with trade secrets regarding: Inventions,
the strategic planning initiatives; business development plans; budgets; financial information; management training; future business
plans; and operational strategies and procedures. Executive understands that any breach of Sections 5 or 7 will also constitute
a misappropriation of Company’s proprietary rights, and may constitute a theft of Company’s trade secrets under applicable
local, state, and federal statutes, and will result in a claim for injunctive relief, damages, and/or criminal sanctions and penalties
against Executive by Company, and possibly others. Executive acknowledges that any breach of Sections 4, 5, 6, 7 or 8 will cause
Company immediate and irreparable injury and damage, for which monetary relief would be inadequate or difficult to quantify. Company
will be entitled to, in addition to all other remedies available to it, injunctive relief and specific performance to prevent a
breach and to secure the enforcement of Sections 4, 5, 6, 7 or 8. Executive further acknowledges that the covenants set forth in
Sections 4, 5, 6, 7 and 8 shall survive the Date of Termination in accordance with their terms

 

    	9

    	 

    

 

10. Miscellaneous
Provisions.

 

10.1Severability.
If, in any jurisdiction, any term or provision hereof is determined to be invalid or unenforceable, (a) the remaining terms and
provisions hereof shall be unimpaired; (b) any such invalidity or unenforceability in any jurisdiction shall not invalidate or
render unenforceable such term or provision in any other jurisdiction; and (c) the invalid or unenforceable term or provision shall,
for purposes of such jurisdiction, be deemed replaced by a term or provision that is valid and enforceable and that comes closest
to expressing the intention of the invalid or unenforceable term or provision.

 

10.2Execution
in Counterparts. This Agreement may be executed in one or more counterparts, and by the two parties hereto in separate counterparts,
each of which shall be deemed to be an original and all of which taken together shall constitute one and the same agreement (and
all signatures need not appear on any one counterpart), and this Agreement shall become effective when one or more counterparts
has been signed by each of the parties hereto and delivered to each of the other parties hereto. This Agreement, once executed
by a Party, may be delivered to the other Party hereto by facsimile or electronic transmission of a copy of this Agreement bearing
the signature of the Party so delivering this Agreement. A faxed or electronically delivered signature shall have the same legally
binding effect as an original signature.

 

10.3.Notices.
All notices, requests, demands and other communications hereunder shall be in writing and shall be deemed duly given upon receipt
when delivered by hand, overnight delivery or facsimile (with confirmed delivery), or three (3) business days after posting, when
delivered by registered or certified mail or private courier service, postage prepaid, return receipt requested, as follows:

 

    	10

    	 

    

 

 

	
        If to Company, to:

         
	 
	
        Elite Pharmaceuticals, Inc.

        165 Ludlow Avenue

        Northvale, New Jersey

        Facsimile No.: (201) 391-7693

        Attn: Chairman

 

 

	
        If to Executive, to:

         
	 
	
        Nasrat Hakim

        20 Kilmer Drive

        Hillsborough, New Jersey, 08844

        Facsimile No.: (908) 450-1318

 

or to such other address(es) as a party
hereto shall have designated by like notice to the other parties hereto.

 

10.4.Amendment.
No provision of this Agreement may be modified, amended, waived or discharged in any manner except by a written instrument executed
by both Company and Executive.

 

10.5.Entire Agreement.
Except as specifically provided herein, this Agreement constitutes the entire agreement of the parties hereto with respect
to the subject matter hereof, and supersedes all prior agreements and understandings of the parties hereto, oral or written.
Company and Executive shall execute and deliver all such further documents as may be necessary to carry out the intent of the preceding
sentence.

 

10.6.Applicable
Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New Jersey applicable to
contracts made and to be wholly performed therein.

 

10.7.Headings.
The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the
meaning or interpretation of any of the terms or provisions of this Agreement.

 

10.8.Binding Effect;
Successors and Assigns. Executive may not delegate any of his duties or assign any of his rights hereunder. This Agreement
shall inure to the benefit of, and be binding upon, the parties hereto and their respective heirs, legal representatives and beneficiaries,
successors and permitted assigns. Company shall require any successor (whether direct or indirect and whether by purchase, merger,
consolidation or otherwise) to all or substantially all of the business and/or assets of Company, by an agreement in form and substance
reasonably satisfactory to Executive, to expressly assume and agree to perform this Agreement in the same manner and to the same
extent that Company would be required to perform if no such succession had taken place.

 

    	11

    	 

    

 

10.9.Waiver.
The failure of either of the parties hereto to at any time enforce any of the provisions of this Agreement shall not be deemed
or construed to be a waiver of any such provision, nor to in any way affect the validity of this Agreement or any provision
hereof or the right of either of the parties hereto thereafter to enforce each and every provision of this Agreement. No waiver
of any breach of any of the provisions of this Agreement shall be construed or deemed to be a waiver of any other or subsequent
breach.

 

10.10.Capacity,
etc. Each of Executive and Company hereby represents and warrants to the other that, as the case may be: (a) he or it has full
power, authority and capacity to execute and deliver this Agreement and to perform his or its obligations hereunder; (b)
such execution, delivery and performance shall not (and with the giving of notice or lapse of time or both would not) result in
the breach of any agreements or other obligations to which he or it is a party or he or it is otherwise bound or violate any law;
and (c) this Agreement is his or its valid and binding obligation enforceable in accordance with its terms.

 

10.11.Enforcement;
Jurisdiction. If any party institutes legal action to enforce or interpret the terms and conditions of this Agreement, the
prevailing party shall be awarded reasonable attorneys’ fees at all trial and appellate levels and the expenses and
costs incurred by such prevailing party in connection therewith. Any legal action, suit or proceeding, in equity or at law, arising
out of or relating to this Agreement shall be instituted exclusively in the State or Federal courts located in the State of New
Jersey and each party agrees not to assert, by way of motion, as a defense or otherwise, in any such action, suit or proceeding,
any claim that such party is not subject personally to the jurisdiction of any such court, that the action, suit or proceeding
is brought in an inconvenient forum, that the venue of the action, suit or proceeding is improper or should be transferred, or
that this Agreement or the subject matter hereof may not be enforced in or by any such court. Each party further irrevocably submits
to the jurisdiction of any such court in any such action, suit or proceeding. Any and all service of process and any other notice
in any such action, suit or proceeding shall be effective against any party if given personally or by registered or certified mail,
return receipt requested or by any other means of mail that requires a signed receipt, postage prepaid, mailed to such party as
herein provided. Nothing herein contained shall be deemed to affect or limit the right of any party to serve process in any other
manner permitted by applicable law.

 

10.12.Advice of
Counsel. Executive represents and warrants that he has had full opportunity to seek advice and representation by independent
counsel of his own choosing in connection with the interpretation, negotiation and execution of this Agreement.

 

[SIGNATURE PAGE FOLLOWS]

 

 

    	12

    	 

    

 

IN WITNESS WHEREOF, this
Agreement has been executed and delivered by the parties hereto as of the date first above written.

 

 

	 	Elite Pharmaceuticals, Inc.
	 	 	 
	 	By: 	 
	 	 	Name:  Jerry Treppel
	 	 	Title:  Chairman & Chief Executive Officer
	 	 	 
	 	By: 	 
	 	 	Name:  Nasrat Hakim

 

 

 

 

 

 

    	13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}]]